Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieran F Docherty

Showing results (121-130 of 143) with videos related to

Pageof 15
Sort By:
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
Journal of Cardiac Failure|September 8, 2023
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFKieran F Docherty, John J V McMurray, Rafael Diaz, et al.
European Journal of Heart Failure|January 4, 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trialKieran F Docherty, John J V McMurray, Brian L Claggett, et al.
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 16, 2026
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HFAlasdair D Henderson, Kieran F Docherty, Atefeh Talebi, et al.
JACC. Heart Failure|January 2, 2023
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HFCarly Adamson, Paul Welsh, Kieran F Docherty, et al.
European Heart Journal|May 23, 2023
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVERJawad H Butt, Toru Kondo, Mingming Yang, et al.
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
European Heart Journal|May 21, 2023
Dapagliflozin vs. metolazone in heart failure resistant to loop diureticsSu Ern Yeoh, Joanna Osmanska, Mark C Petrie, et al.
The Lancet. Diabetes & Endocrinology|December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trialsPeter Rossing, Silvio E Inzucchi, Priya Vart, et al.
Pageof 15

Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
European Journal of Heart Failure|December 15, 2024
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)Jaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
Journal of Cardiac Failure|September 8, 2023
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFKieran F Docherty, John J V McMurray, Rafael Diaz, et al.
European Journal of Heart Failure|January 4, 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trialKieran F Docherty, John J V McMurray, Brian L Claggett, et al.
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 16, 2026
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HFAlasdair D Henderson, Kieran F Docherty, Atefeh Talebi, et al.
JACC. Heart Failure|January 2, 2023
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HFCarly Adamson, Paul Welsh, Kieran F Docherty, et al.
European Heart Journal|May 23, 2023
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVERJawad H Butt, Toru Kondo, Mingming Yang, et al.
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
European Heart Journal|May 21, 2023
Dapagliflozin vs. metolazone in heart failure resistant to loop diureticsSu Ern Yeoh, Joanna Osmanska, Mark C Petrie, et al.
The Lancet. Diabetes & Endocrinology|December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trialsPeter Rossing, Silvio E Inzucchi, Priya Vart, et al.
Pageof 15